Concord Biotech Ltd

Concord Biotech has made an equity investment of USD 1,500 in Stellon Biotech Inc. This investment represents the subscription of 15 million equity shares at a price of USD 0.0001 per share resulting into 75% ownership in Stellon Biotech Inc to expand Company's business operations in USA. Stellon Biotech Inc. is a Delaware-incorporated pharmaceutical company established in December 2024. As a newly formed entity, Stellon is currently in its pre-revenue phase and was specifically created to support the marketing and commercialization of products developed by Concord Biotech. Powered by Capital Market - Live

The scrip had declined 15.63% in seven sessions to end at Rs 1,780.75 yesterday, from its recent closing high of Rs 2,110.55 recorded on 13 June 2025. On a year-to-date (YTD) basis, the stock has fallen by 15.13% while the S&P BSE Sensex and the S&P BSE 500 index have gained 5.10% and 3.15%, respectively. On the technical front, the stock's RSI (14) was currently at 47.428. An RSI reading of 70 or above indicates an overbought condition. A reading of 30 or below indicates an oversold condition. On the daily chart, the scrip is trading below its 10-day and 20-day simple moving averages (SMAs) placed at 1959.50 and 1928.23, respectively. It is, however, trading above 100-day SMA positioned at 1750.69. In a regulatory filing made yesterday, Concord Biotech said that it has received an establishment inspection report (EIR) from the US Food and Drug Administration (US FDA) for the inspection carried out by them at its API facility at Dholka from 28 April 2025 till 2 May 2025. It further said that the USFDA has officially concluded its inspection, which is now closed under 21 CFR 20.64(d)(3). This closure indicates that no regulatory action is required, and the facility is permitted to continue its operations without any restrictions,' Concord Biotech stated. Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment. Powered by Capital Market - Live

Concord Biotech has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at its API facility at Dholka from 28 April 2025 till 2 May 2025. Powered by Capital Market - Live

Concord Biotech announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 10.7 per equity Share (i.e. 1070%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Concord Biotech rose 47.75% to Rs 140.39 crore in the quarter ended March 2025 as against Rs 95.02 crore during the previous quarter ended March 2024. Sales rose 34.77% to Rs 429.88 crore in the quarter ended March 2025 as against Rs 318.97 crore during the previous quarter ended March 2024. For the full year,net profit rose 20.62% to Rs 371.64 crore in the year ended March 2025 as against Rs 308.10 crore during the previous year ended March 2024. Sales rose 18.01% to Rs 1200.09 crore in the year ended March 2025 as against Rs 1016.94 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales429.88318.97 35 1200.091016.94 18 OPM %43.9441.41 -42.0842.44 - PBDT198.16142.44 39 548.93466.16 18 PBT183.54128.72 43 494.55412.57 20 NP140.3995.02 48 371.64308.10 21 Powered by Capital Market - Live

Concord Biotech will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live

Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis. This approval reinforces our capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market, Concord Biotech said in a statement. According to IQVIA, the market size of Teriflunomide tablets is approximately $402 million in the US, and the global market size is approximately $908 million, indicating significant opportunities for expansion in the US and the global market. Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment. The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. The scrip shed 0.17% to currently trade at Rs 1595.10 on the BSE. Powered by Capital Market - Live

Concord Biotech has successfully commissioned and commenced production of injectable at its new manufacturing facility (Unit 4) situated at Valthera. Powered by Capital Market - Live

Concord Biotech has invested Rs 6.09 crore through subscription to Right issue of shares in CLEAN MAX EVERGLADES (Clean Max) for installation of hybrid renewable energy plant in the State of Gujarat having a wind capacity of 6.6 MW and solar capacity of 3.3 MWp DC for the plant of the Company situated at Dholka. Investment in 26% equity share capital in Clean Max, renewable energy aligns with the Company's commitment to sustainability and it's focused efforts to address environmental challenges. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the Company's commitment to environmental responsibility, ensuring compliance with evolving environmental regulations, and supporting sustainable growth while enhancing operational efficiency. Powered by Capital Market - Live

This rebound follows a steep decline of 28.15% over the preceding seven trading sessions, triggered by the company's disappointing third-quarter financial results for the 2025 fiscal year (Q3FY25). The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. Profit before tax (PBT) fell 2% YoY to Rs 75.92 crore during the quarter. EBITDA stood at Rs 98 crore, registering de-growth of 8% compared with Rs 105.9 crore in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24. Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide. Powered by Capital Market - Live